Skip to main content
NCBI home page
The EMBO Journal logoLink to The EMBO Journal
. 1991 Apr;10(4):919–926. doi: 10.1002/j.1460-2075.1991.tb08025.x

Epstein Barr virus/complement C3d receptor is an interferon alpha receptor.

A X Delcayre 1, F Salas 1, S Mathur 1, K Kovats 1, M Lotz 1, W Lernhardt 1
PMCID: PMC452735  PMID: 1849076

Abstract

Interferon alpha contains a sequence motif similar to the complement receptor type two (CR2/CD21) binding site on complement fragment C3d. Antibodies against a peptide with the CR2 binding sequence on C3d react with a peptide carrying the IFN alpha CR2 binding motif (residues 92-99) and with recombinant IFN alpha. The IFN alpha-derived peptide, as well as recombinant IFN alpha, inhibits C3bi/C3d interaction with CR2 on the Burkitt lymphoma Raji. The direct interaction of IFN alpha and CR2 is inhibited by polyclonal anti-IFN alpha, anti-CR2 and anti-C3d peptide antibodies as well as by C3bi/C3d, EBV coat protein gp350/220 and IFN but not by IFN gamma. [125I]IFN alpha binding to Raji cells is inhibited by polyclonal anti-IFN alpha and anti-CR2 antibodies, by peptides with the CR2 binding motif and partially by C3bi/C3d. Monoclonal anti-CR2 antibody HB5, but not OKB-7, blocks IFN alpha binding to Raji cells. CR2 or CR2-like molecules may therefore be the major IFN alpha receptors on B lymphocytes.

Full text

PDF
919

Images in this article

922Image
on p.922

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aguet M., Dembić Z., Merlin G. Molecular cloning and expression of the human interferon-gamma receptor. Cell. 1988 Oct 21;55(2):273–280. doi: 10.1016/0092-8674(88)90050-5. [DOI] [PubMed] [Google Scholar]
  2. Aguet M. High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor. Nature. 1980 Apr 3;284(5755):459–461. doi: 10.1038/284459a0. [DOI] [PubMed] [Google Scholar]
  3. Ahearn J. M., Fearon D. T. Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol. 1989;46:183–219. doi: 10.1016/s0065-2776(08)60654-9. [DOI] [PubMed] [Google Scholar]
  4. Barel M., Charriaut C., Frade R. Isolation and characterization of a C3b receptor-like molecule from membranes of a human B lymphoblastoid cell line (Raji). FEBS Lett. 1981 Dec 21;136(1):111–114. doi: 10.1016/0014-5793(81)81225-2. [DOI] [PubMed] [Google Scholar]
  5. Barel M., Fiandino A., Delcayre A. X., Lyamani F., Frade R. Monoclonal and anti-idiotypic anti-EBV/C3d receptor antibodies detect two binding sites, one for EBV and one for C3d on glycoprotein 140, the EBV/C3dR, expressed on human B lymphocytes. J Immunol. 1988 Sep 1;141(5):1590–1595. [PubMed] [Google Scholar]
  6. Carel J. C., Myones B. L., Frazier B., Holers V. M. Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem. 1990 Jul 25;265(21):12293–12299. [PubMed] [Google Scholar]
  7. Cooper N. R., Moore M. D., Nemerow G. R. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Annu Rev Immunol. 1988;6:85–113. doi: 10.1146/annurev.iy.06.040188.000505. [DOI] [PubMed] [Google Scholar]
  8. Davis G. L., Balart L. A., Schiff E. R., Lindsay K., Bodenheimer H. C., Jr, Perrillo R. P., Carey W., Jacobson I. M., Payne J., Dienstag J. L. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med. 1989 Nov 30;321(22):1501–1506. doi: 10.1056/NEJM198911303212203. [DOI] [PubMed] [Google Scholar]
  9. Delcayre A. X., Fiandino A., Barel M., Frade R. gp140, the EBV/C3d receptor (CR2) of human B lymphocytes, is involved in cell-free phosphorylation of p120, a nuclear ribonucleoprotein. Eur J Immunol. 1987 Dec;17(12):1827–1833. doi: 10.1002/eji.1830171223. [DOI] [PubMed] [Google Scholar]
  10. Di Bisceglie A. M., Martin P., Kassianides C., Lisker-Melman M., Murray L., Waggoner J., Goodman Z., Banks S. M., Hoofnagle J. H. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989 Nov 30;321(22):1506–1510. doi: 10.1056/NEJM198911303212204. [DOI] [PubMed] [Google Scholar]
  11. Faltynek C. R., Branca A. A., McCandless S., Baglioni C. Characterization of an interferon receptor on human lymphoblastoid cells. Proc Natl Acad Sci U S A. 1983 Jun;80(11):3269–3273. doi: 10.1073/pnas.80.11.3269. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fingeroth J. D., Weis J. J., Tedder T. F., Strominger J. L., Biro P. A., Fearon D. T. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A. 1984 Jul;81(14):4510–4514. doi: 10.1073/pnas.81.14.4510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Frade R., Barel M., Krikorian L., Charriaut C. Analysis of gp 140, a C3b-binding membrane component present on Raji cells: a comparison with factor H. Eur J Immunol. 1984 Jun;14(6):542–548. doi: 10.1002/eji.1830140611. [DOI] [PubMed] [Google Scholar]
  14. Fujisaku A., Harley J. B., Frank M. B., Gruner B. A., Frazier B., Holers V. M. Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor. J Biol Chem. 1989 Feb 5;264(4):2118–2125. [PubMed] [Google Scholar]
  15. Hannigan G. E., Gewert D. R., Williams B. R. Characterization and regulation of alpha-interferon receptor expression in interferon-sensitive and -resistant human lymphoblastoid cells. J Biol Chem. 1984 Aug 10;259(15):9456–9460. [PubMed] [Google Scholar]
  16. Holguin M. H., Kurtz C. B., Parker C. J., Weis J. J., Weis J. H. Loss of human CR1- and murine Crry-like exons in human CR2 transcripts due to CR2 gene mutations. J Immunol. 1990 Sep 15;145(6):1776–1781. [PubMed] [Google Scholar]
  17. Iida K., Nadler L., Nussenzweig V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med. 1983 Oct 1;158(4):1021–1033. doi: 10.1084/jem.158.4.1021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Karasuyama H., Tohyama N., Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J Exp Med. 1989 Jan 1;169(1):13–25. doi: 10.1084/jem.169.1.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Kurtz C. B., O'Toole E., Christensen S. M., Weis J. H. The murine complement receptor gene family. IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share homologous domains with both human CR2 and CR1. J Immunol. 1990 May 1;144(9):3581–3591. [PubMed] [Google Scholar]
  20. Lane H. C., Kovacs J. A., Feinberg J., Herpin B., Davey V., Walker R., Deyton L., Metcalf J. A., Baseler M., Salzman N. Anti-retroviral effects of interferon-alpha in AIDS-associated Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1218–1222. doi: 10.1016/s0140-6736(88)90811-2. [DOI] [PubMed] [Google Scholar]
  21. Langer J. A., Pestka S. Procedures for studying binding of interferon to human cells in suspension cultures. Methods Enzymol. 1986;119:305–311. doi: 10.1016/0076-6879(86)19046-x. [DOI] [PubMed] [Google Scholar]
  22. Lotz M., Tsoukas C. D., Fong S., Carson D. A., Vaughan J. H. Regulation of Epstein-Barr virus infection by recombinant interferons. Selected sensitivity to interferon-gamma. Eur J Immunol. 1985 May;15(5):520–525. doi: 10.1002/eji.1830150518. [DOI] [PubMed] [Google Scholar]
  23. Lowell C. A., Klickstein L. B., Carter R. H., Mitchell J. A., Fearon D. T., Ahearn J. M. Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med. 1989 Dec 1;170(6):1931–1946. doi: 10.1084/jem.170.6.1931. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Markwell M. A., Fox C. F. Surface-specific iodination of membrane proteins of viruses and eucaryotic cells using 1,3,4,6-tetrachloro-3alpha,6alpha-diphenylglycoluril. Biochemistry. 1978 Oct 31;17(22):4807–4817. doi: 10.1021/bi00615a031. [DOI] [PubMed] [Google Scholar]
  25. Melchers F., Erdei A., Schulz T., Dierich M. P. Growth control of activated, synchronized murine B cells by the C3d fragment of human complement. Nature. 1985 Sep 19;317(6034):264–267. doi: 10.1038/317264a0. [DOI] [PubMed] [Google Scholar]
  26. Merlin G., Falcoff E., Aguet M. 125I-labelled human interferons alpha, beta and gamma: comparative receptor-binding data. J Gen Virol. 1985 May;66(Pt 5):1149–1152. doi: 10.1099/0022-1317-66-5-1149. [DOI] [PubMed] [Google Scholar]
  27. Mittler R. S., Talle M. A., Carpenter K., Rao P. E., Goldstein G. Generation and characterization of monoclonal antibodies reactive with human B lymphocytes. J Immunol. 1983 Oct;131(4):1754–1761. [PubMed] [Google Scholar]
  28. Mogensen K. E., Bandu M. T. Kinetic evidence for an activation step following binding of human interferon alpha 2 to the membrane receptors of Daudi cells. Eur J Biochem. 1983 Aug 1;134(2):355–364. doi: 10.1111/j.1432-1033.1983.tb07575.x. [DOI] [PubMed] [Google Scholar]
  29. Mogensen K. E., Bandu M. T., Vignaux F., Aguet M., Gressner I. Binding of 125I-labelled human alpha interferon to human lymphoid cells. Int J Cancer. 1981 Nov 15;28(5):575–582. doi: 10.1002/ijc.2910280508. [DOI] [PubMed] [Google Scholar]
  30. Moore M. D., DiScipio R. G., Cooper N. R., Nemerow G. R. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J Biol Chem. 1989 Dec 5;264(34):20576–20582. [PubMed] [Google Scholar]
  31. Myones B. L., Ross G. D. Identification of a spontaneously shed fragment of B cell complement receptor type two (CR2) containing the C3d-binding site. Complement. 1987;4(2):87–98. doi: 10.1159/000463012. [DOI] [PubMed] [Google Scholar]
  32. Nemerow G. R., Houghten R. A., Moore M. D., Cooper N. R. Identification of an epitope in the major envelope protein of Epstein-Barr virus that mediates viral binding to the B lymphocyte EBV receptor (CR2). Cell. 1989 Feb 10;56(3):369–377. doi: 10.1016/0092-8674(89)90240-7. [DOI] [PubMed] [Google Scholar]
  33. Pestka S., Langer J. A., Zoon K. C., Samuel C. E. Interferons and their actions. Annu Rev Biochem. 1987;56:727–777. doi: 10.1146/annurev.bi.56.070187.003455. [DOI] [PubMed] [Google Scholar]
  34. Pfeffer L. M., Donner D. B. The down-regulation of alpha-interferon receptors in human lymphoblastoid cells: relation to cellular responsiveness to the antiproliferative action of alpha-interferon. Cancer Res. 1990 May 1;50(9):2654–2657. [PubMed] [Google Scholar]
  35. Sauvageau G., Stocco R., Kasparian S., Menezes J. Epstein-Barr virus receptor expression on human CD8+ (cytotoxic/suppressor) T lymphocytes. J Gen Virol. 1990 Feb;71(Pt 2):379–386. doi: 10.1099/0022-1317-71-2-379. [DOI] [PubMed] [Google Scholar]
  36. Servis C., Lambris J. D. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells. J Immunol. 1989 Apr 1;142(7):2207–2212. [PubMed] [Google Scholar]
  37. Strander H. Interferon treatment of human neoplasia. Adv Cancer Res. 1986;46:1–265. [PubMed] [Google Scholar]
  38. Tedder T. F., Clement L. T., Cooper M. D. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J Immunol. 1984 Aug;133(2):678–683. [PubMed] [Google Scholar]
  39. Toothaker L. E., Henjes A. J., Weis J. J. Variability of CR2 gene products is due to alternative exon usage and different CR2 alleles. J Immunol. 1989 May 15;142(10):3668–3675. [PubMed] [Google Scholar]
  40. Traub A., Feinstein S., Gez M., Lazar A., Mizrahi A. Purification and properties of the alpha-interferon receptor of human lymphoblastoid (Namalva) cells. J Biol Chem. 1984 Nov 25;259(22):13872–13877. [PubMed] [Google Scholar]
  41. Uzé G., Lutfalla G., Gresser I. Genetic transfer of a functional human interferon alpha receptor into mouse cells: cloning and expression of its cDNA. Cell. 1990 Jan 26;60(2):225–234. doi: 10.1016/0092-8674(90)90738-z. [DOI] [PubMed] [Google Scholar]
  42. Weis J. J., Tedder T. F., Fearon D. T. Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A. 1984 Feb;81(3):881–885. doi: 10.1073/pnas.81.3.881. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Weis J. J., Toothaker L. E., Smith J. A., Weis J. H., Fearon D. T. Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med. 1988 Mar 1;167(3):1047–1066. doi: 10.1084/jem.167.3.1047. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Weissmann C., Weber H. The interferon genes. Prog Nucleic Acid Res Mol Biol. 1986;33:251–300. doi: 10.1016/s0079-6603(08)60026-4. [DOI] [PubMed] [Google Scholar]
  45. Young L. S., Dawson C. W., Brown K. W., Rickinson A. B. Identification of a human epithelial cell surface protein sharing an epitope with the C3d/Epstein-Barr virus receptor molecule of B lymphocytes. Int J Cancer. 1989 May 15;43(5):786–794. doi: 10.1002/ijc.2910430508. [DOI] [PubMed] [Google Scholar]
  46. de Wit R., Schattenkerk J. K., Boucher C. A., Bakker P. J., Veenhof K. H., Danner S. A. Clinical and virological effects of high-dose recombinant interferon-alpha in disseminated AIDS-related Kaposi's sarcoma. Lancet. 1988 Nov 26;2(8622):1214–1217. doi: 10.1016/s0140-6736(88)90810-0. [DOI] [PubMed] [Google Scholar]

Articles from The EMBO Journal are provided here courtesy of Nature Publishing Group

RESOURCES